Cargando…

Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience

The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 33–83) with advanced NETs having enhanced SSTR expression, treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filice, A., Fraternali, A., Frasoldati, A., Asti, M., Grassi, E., Massi, L., Sollini, M., Froio, A., Erba, P. A., Versari, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425839/ https://www.ncbi.nlm.nih.gov/pubmed/22934111 http://dx.doi.org/10.1155/2012/320198

Ejemplares similares

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

SPECT/CT with radiolabeled somatostatin analogues in the evaluation of systemic granulomatous infections
por: Monteiro, Paulo Henrique Silva, et al.
Publicado: (2017)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?
por: Cuccurullo, Vincenzo, et al.
Publicado: (2017)

(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study
por: Taralli, Silvia, et al.
Publicado: (2018)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
por: O'Byrne, K. J., et al.
Publicado: (1994)

The Role of Imaging in the Diagnosis of Recurrence of Primary Seminal Vesicle Adenocarcinoma
por: Sollini, Martina, et al.
Publicado: (2014)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
por: Costa, Ricardo, et al.
Publicado: (2013)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
por: Eychenne, Romain, et al.
Publicado: (2020)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
por: Fani, Melpomeni, et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs
por: Crespo-Jara, Aurora, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7kamv9hsjbde1h3vl9s6n2oae3